MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

AdvaMed Enlists Ubl's Replacement from Biotech Lobby

AdvaMed Enlists Ubl's Replacement from Biotech Lobby
The largest device lobby in the U.S. names a new president and CEO who comes from BIO and held positions with the Department of Health and Human Services.

The largest device lobby in the U.S. names a new president and CEO who comes from BIO and held positions with the Department of Health and Human Services.

Arundhati Parmar

Back in September, Stephen Ubl jumped ship from being chief of AdvaMed to taking the reins at PhrMA (Pharmaceutical Research and Manufacturers of America).

And now the largest device lobby in the U.S. has sought his replacement from another lobby group: BIO. AdvaMed announced Thursday that Scott Whitaker, previously chief operating officer of BIO (Biotechnology Innovation Organization), will become president and CEO starting April 4. 

"It is a tremendous privilege to join AdvaMed and represent such an innovative and life changing industry," Whitaker said in a statement.  "Given the many health care challenges throughout the world, it is critical that we work together to create a policy and regulatory environment that will allow this industry to continue to discover, develop and deliver innovative medical technologies to patients. It is essential that patients everywhere have full access to the benefits of medical technology."

Register for the BIOMEDevice Boston Conference, April 13-14, to stay on top of industry trends.

Whitaker also knows the ins and outs of government having been chief of staff and assistant secretary for legislation at the Department of Health and Human Services before joining the biotech lobby group.

He joins AdvaMed at a time when the 2.3% device tax has been temporarily paused. Short of full repeal that some expect may well happen, it was a significant achievement by AdvaMed which rallied bipartisan support to achieve the 2-year pause.

But that is relatively a minor head wind compared to other challenges the industry faces: a slowdown in Asian markets even as pressures at home grow through bundled payments, performance-based pricing contracts and hospital consolidating medtech vendors.  

Arundhati Parmar is senior editor at MD+DI. Reach her at [email protected] and on Twitter @aparmarbb 

Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish